Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

81. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 8413388 1993 10 26 1993 10 26 2013 11 21 0028-4793 329 17 1993 Oct 21 The New England journal of medicine N. Engl. J. Med. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 1225-30 Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (...) remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of GVHD. One hundred fifty patients with either acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, or lymphoblastic lymphoma in first complete remission were enrolled in the study. All the patients were given fractionated total-body irradiation (1320 cGy) and etoposide (60 mg per kilogram of body weight

NEJM1993

82. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma.

Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. 1997850 1991 04 02 1991 04 02 2013 11 21 0028-4793 324 12 1991 Mar 21 The New England journal of medicine N. Engl. J. Med. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. 788-94 Relapse after the treatment of acute asthma in the emergency room is common (occurring in 25 to 30 percent of cases (...) ) and is not accurately predicted by any available measurements. We studied the usefulness of prednisone in reducing this high rate of relapse. One hundred twenty-two patients treated in the emergency room for acute exacerbations of asthma were assigned in a randomized, double-blind fashion to receive at discharge either prednisone for eight days (the dose being tapered from 40 to 0 mg per day) or matching placebo. Ninety-three were subsequently discharged from the emergency room and participated in the trial

NEJM1991

83. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone.

Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. 2109195 1990 05 15 1990 05 15 2013 11 21 0028-4793 322 17 1990 Apr 26 The New England journal of medicine N. Engl. J. Med. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. 1183-8 Prostaglandins of the E series have been shown to have (...) immunosuppressive properties. To study the effects of the prostaglandin E1 analogue misoprostol on renal function and graft rejection after transplantation, we conducted a randomized, double-blind, placebo-controlled trial in 77 renal-allograft recipients. The subjects received misoprostol (200 micrograms four times daily by mouth; n = 38) or placebo (n = 39) for the first 12 weeks after transplantation, in addition to standard immunosuppression with cyclosporine and prednisone. They were then observed

NEJM1990

84. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. 2195346 1990 08 15 1990 08 15 2016 11 23 0028-4793 323 5 1990 Aug 02 The New England journal of medicine N. Engl. J. Med. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. 295-301 Chronic (...) hepatitis B is a common and often progressive liver disorder for which there is no accepted therapy. To assess the efficacy of treatment with interferon, we randomly assigned patients with chronic hepatitis B to one of the following regimens: prednisone for 6 weeks followed by 5 million units of recombinant interferon alfa-2b daily for 16 weeks; placebo followed by 5 million units of interferon daily for 16 weeks; placebo followed by 1 million units of interferon daily for 16 weeks; or observation

NEJM1990

85. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy.

A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. 2643046 1989 02 17 1989 02 17 2013 11 21 0028-4793 320 4 1989 Jan 26 The New England journal of medicine N. Engl. J. Med. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. 210-5 We conducted a prospective randomized study in which patients with biopsy-confirmed idiopathic membranous nephropathy were assigned to receive either a six-month course (...) of prednisone given on alternate days (45 mg per square meter of body-surface area; n = 81) or no specific treatment (n = 77). The mean duration of follow-up was 48 months. Patients in the prednisone group (median age, 46 years) entered with a mean disease duration of 15 months, a median creatinine clearance of 1.2 ml per second per 1.73 m2 (range, 0.25 to 2.6), and a median rate of urinary protein excretion of 6.8 g per day (0.3 to 26). The annual change in the corrected creatinine clearance at six months

NEJM1989

86. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. 2657428 1989 07 07 1989 07 07 2013 11 21 0028-4793 320 24 1989 Jun 15 The New England journal of medicine N. Engl. J. Med. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. 1592-7 We performed a randomized, double-blind, controlled six-month trial of prednisone in 103 boys with Duchenne's muscular dystrophy (age, 5 to 15 years). The patients were assigned to one (...) of three regimens: prednisone, 0.75 mg per kilogram of body weight per day (n = 33); prednisone, 1.5 mg per kilogram per day (n = 34); or placebo (n = 36). The groups were initially comparable in all measures of muscle function. Both prednisone groups had significant improvement of similar degree in the summary scores of muscle strength and function. Improvement began as early as one month and peaked by three months. At six months the high-dose prednisone group, as compared with the placebo group, had

NEJM1989

87. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy.

A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. 2677721 1989 11 07 1989 11 07 2013 11 21 0028-4793 321 16 1989 Oct 19 The New England journal of medicine N. Engl. J. Med. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. 1061-8 Although prednisone has been used to treat patients with idiopathic dilated cardiomyopathy, its efficacy has not been rigorously studied. We therefore randomly assigned 102 patients to either (...) treatment with prednisone (60 mg per day) or a control group. At three months, improvement, defined prospectively as an increase in the ejection fraction of greater than or equal to 5 percentage points, was observed in 53 percent of the patients receiving prednisone and 27 percent of the controls (P = 0.005). The mean (+/- SE) ejection fraction increased 4.3 +/- 1.5 percentage points (from 17.9 +/- 1.0 to 22.2 +/- 1.6 percent) in the prednisone group, as compared with 2.1 +/- 0.8 percentage points (from

NEJM1989

88. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.

Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. 2519530 1989 12 06 1989 12 06 2013 11 21 0028-4793 321 20 1989 Nov 16 The New England journal of medicine N. Engl. J. Med. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. 1353-9 It is uncertain what is the most appropriate medical therapy for patients with severe Graves' ophthalmopathy. Therefore, we carried out a single-blind, randomized clinical trial to compare the efficacy (...) of prednisone with that of cyclosporine in 36 patients who had been euthyroid for at least two months. The two groups, each consisting of 18 patients, were similar in age, sex, and the duration and severity of ophthalmopathy. The initial dose of cyclosporine was 7.5 mg per kilogram of body weight per day, and that of prednisone was 60 mg per day, which was subsequently tapered to 20 mg per day. During the 12-week treatment period, 11 prednisone-treated and 4 cyclosporine-treated patients responded

NEJM1989

89. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. 2893190 1988 03 23 1988 03 23 2015 06 16 0140-6736 1 8582 1988 Feb 20 Lancet (London, England) Lancet Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. 380-3 Two regimens of steroid treatment for the initial attack of idiopathic (...) nephrotic syndrome in children were compared in a controlled multicentre study. Short-course prednisone therapy consisted of 60 mg/m2 per 24 h until proteinuria had disappeared for 3 days, followed by 40 mg/m2 per 48 h until complete remission had occurred. The standard prednisone therapy was 60 mg/m2 per 24 h for 4 weeks, followed by 40 mg/m2 per 48 h for 4 weeks. 61 children with a first attack of idiopathic nephrotic syndrome were allocated at random to these groups. Urinary remission in the short

Lancet1988

90. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. 3045545 1988 09 23 1988 09 23 2013 11 21 0028-4793 319 10 1988 Sep 08 The New England journal of medicine N. Engl. J. Med. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. 599-604 We randomly assigned 46 patients (mean age, 11.7 years; range, 4.5 to 32.8) with newly diagnosed insulin-dependent diabetes mellitus within two weeks (...) , were insulin independent at one year. Two of these continue to receive azathioprine without insulin after more than 27 months of follow-up. The response to immunosuppression correlated with older age, better initial metabolic status, and lymphopenia (less than 1800 lymphocytes per cubic millimeter) resulting from immunosuppression. The side effects of azathioprine included vomiting in one patient and mild hair loss in several others. Prednisone use resulted in a transient cushingoid appearance

NEJM1988

91. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. 3511372 1986 03 26 1986 03 26 2013 11 21 0028-4793 314 10 1986 Mar 06 The New England journal of medicine N. Engl. J. Med. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. 614-9 We evaluated renal function in 107 patients with active lupus nephritis who participated in long-term randomized therapeutic trials (median follow-up, seven years). For patients taking oral prednisone alone (...) , the probability of renal failure began to increase substantially after five years of observation. Renal function was better preserved in patients who received various cytotoxic-drug therapies, but the difference was statistically significant only for intravenous cyclophosphamide plus low-dose prednisone as compared with high-dose prednisone alone (P = 0.027). The advantage of treatment with intravenous cyclophosphamide over oral prednisone alone was particularly apparent in the high-risk subgroup of patients

NEJM1986

92. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. 2863676 1985 10 24 1985 10 24 2015 06 16 0140-6736 2 8457 1985 Sep 28 Lancet (London, England) Lancet Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. 686-8 A randomised, double-blind, placebo-controlled study examined the effects of alternate-day prednisone therapy on morbidity and progression of lung disease in cystic fibrosis (CF). At baseline (...) the patients (aged 1-12 years) had mild to moderate lung disease, and the prednisone group did not differ significantly from the placebo group for any values measured. After 4 years, the prednisone-treated group had significant advantages over the placebo group for height, weight, vital capacity, forced expiratory volume in 1 s, peak flow rate, erythrocyte sedimentation rate, and serum IgG. The prednisone-treated group required 9 admissions to hospital for CF-related pulmonary disease compared with 35

Lancet1985

93. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis.

Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. 6390198 1984 12 27 1984 12 27 2013 11 21 0028-4793 311 24 1984 Dec 13 The New England journal of medicine N. Engl. J. Med. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. 1528-33 In an effort to clarify the role of immunosuppressive drugs in the management (...) of lupus nephritis, we pooled data from all published clinical trials in which patients had been randomly assigned to receive either prednisone alone or prednisone plus cyclophosphamide or azathioprine. The pooled analysis showed that patients receiving immunosuppressive drugs had less renal deterioration (P = 0.006), were less likely to have end-stage renal disease (P = 0.023), and were less likely to die from kidney disease (P = 0.024) than patients receiving steroids alone. There were no significant

NEJM1984

94. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie".

Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie". 84259 1979 04 28 1979 04 28 2015 06 16 0140-6736 1 8113 1979 Feb 24 Lancet (London, England) Lancet Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbetsgemeinschaft für Pädiatrische Nephrologie". 401-3 23 children with frequently relapsing minimal-change nephrotic syndrome were treated (...) with alternate-day prednisone (35 mg/m2/48 h) and 25 other patients were treated with intermittent prednisone (40 mg/m2 on three consecutive days out of seven) for six months. This was followed by six months without any maintenance steroid treatment except when relapse required a short period of prednisone therapy until remission. The number of relapsers was significantly lower on alternate-day than on intermittent treatment. In the alternate-day group, the number of relapsers and the rate of relapse

Lancet1979

95. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome.

A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. 388220 1980 01 28 1980 01 28 2013 11 21 0028-4793 301 24 1979 Dec 13 The New England journal of medicine N. Engl. J. Med. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. 1301-6 Seventy-two adults with the nephrotic syndrome without (...) renal insufficiency had a membranous type of renal histology on biopsy. These patients were randomly allocated to at least eight weeks of alternate-day treatment with prednisone or placebo in a multicenter study. Deterioration of glomerular filtration rate was significantly more rapid in placebo-treated than in prednisone-treated patients, and ultimately 10 of 38 given placebo but only one of 34 given prednisone were in renal failure (creatinine more than 5 mg per deciliter [440 mumol per liter

NEJM1979

96. Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer.

Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. 76842 1978 06 17 1978 06 17 2015 06 16 0140-6736 1 8070 1978 Apr 29 Lancet (London, England) Lancet Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. 893-6 172 patients who had had mastectomy for breast (...) cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P.A.M.) or a combination of cyclophosphamide, 5-fluorouracil, and prednisone (C.F.P.) with and without radiotherapy. Tumours recurred significantly more frequently and mortality tended to be higher in P.A.M.-treated patients than in patients on other treatment. The interval between surgery and disease recurrence was significantly shorter for P.A.M.-treated premenopausal but not postmenopausal patients than

Lancet1978

97. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide.

Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. 309095 1978 12 27 1978 12 27 2013 11 21 0028-4793 299 21 1978 Nov 23 The New England journal of medicine N. Engl. J. Med. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. 1151-5 To evaluate the effectiveness of cyclophosphamide in the treatment of lupus nephritis, we designed a prospective study of patients with diffuse (...) proliferative lupus nephritis. Twenty-six patients received prednisone (average dose, 40 mg per day) and 24 combined prednisone (average dose, 29 mg per day) and cyclophosphamide (average dose, 107 mg per day) for six months. Thereafter, all patients received maintenance doses of prednisone. Most of the patients improved (84 per cent) after six months of initial treatment with either program. Early progression of disease, ending mainly in end-stage renal disease, was equally frequent in the two treatment

NEJM1978

98. Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association.

Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association. 51284 1975 11 25 1975 11 25 2015 11 19 0140-6736 2 7933 1975 Sep 13 Lancet (London, England) Lancet Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. A controlled trial by the British Thoracic and Tuberculosis Association. 469-73 (...) Inhaled beclomethasone dipropionate and inhaled betamethasone valerate have been compared with oral prednisone in the treatment of 75 patients with asthma who were starting long-term corticosteroids for the first time. Both of the inhaled corticosteroids controlled asthma as well as did oral prednisone in those who had responded to therapy in the initial period of the trial. A daily dose of 400 mug of inhaled drug was approximately equivalent to 7-5 mg daily of prednisone. Prednisone suppressed

Lancet1975